Axsome Therapeutics' CNS Portfolio Poised for Major Growth - Analyst Predicts Strong FutureBenzinga • 07/22/24
Wall Street Analysts Predict a 49.36% Upside in Axsome (AXSM): Here's What You Should KnowZacks Investment Research • 07/18/24
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem LaboratoriesGlobeNewsWire • 06/05/24
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness MonthGlobeNewsWire • 06/04/24
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024GlobeNewsWire • 05/29/24
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/06/24
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual MeetingGlobeNewsWire • 04/15/24